Market Overview

Morgan Stanley Speculates On Potential Abbott Laboratories Transaction

Share:
Related ABT
Benzinga's M&A Chatter for Thursday August 27, 2015
Benzinga's Volume Movers
Can Top 10 Healthcare Dogs Average 25% Upsides And 27% Net Gains As Of September 2016? (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “Abbott is a unique healthcare asset, with high exposure to emerging markets and consumer- directed businesses, driving the potential for sustainable double digit earnings growth. Leverage opportunities are highly visible in both Nutritionals and Diagnostics, where peer margins demonstrate the potential for improvement. Expectations are low for the established pharma business, which has come under pressure in the developed markets and presents the potential for reacceleration as emerging market mix grows over time and austerity measures are lapped.”

Abbott Laboratories closed on Friday at $38.56.

Latest Ratings for ABT

DateFirmActionFromTo
Aug 2015Credit SuisseAssumesOutperform
Aug 2015JefferiesMaintainsHold
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Get Benzinga's Newsletters